ATAD2 and cancer: We find that the expression of ATAD2 increases in early stages of cancer progression, with a significant increase in ATAD2 expression from CAH lesions to grade 1 endometrioid lesions (P < 0.001) and a further significant increase from grade 1/2 to grade 3 endometrioid endometrial cancers (P < 0.001).